FLASH radiotherapy combined with immunotherapy: From biological mechanisms to blockbuster therapeutics
Translational Oncology · 2025-01 · 51 · 102183
DOI: 10.1016/j.tranon.2024.102183 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Oncology, 2025-01. Verfasst von Yu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sci…. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
FLASH ultra-high dose rate radiotherapy (RT) can effectively exert the protective effect on normal tissue and reduce the risk of treatment-related toxicity, without compromising the killing effect on tumor tissue, resulting in a significant differential biological effect between tumor control and normal tissue damage, namely the FLASH effect. To date, the precise biological details of the FLASH effect remain uncertain. The currently mainstream mechanisms proposed by the academic community include the transient oxygen depletion hypothesis, free radical hypothesis, immune protection hypothesis, and DNA integrity hypothesis, which have attracted increasing attention in recent years. Based on these theoretical principles and numerous investigations on the FLASH effect in vivo and in vitro, the combined application of FLASH and immune checkpoint inhibitors (ICIs) has been considered synergistic and potentially practical. The primary underlying basis is that FLASH might actively preserve the number and function of circulating immune cells, thereby enhancing the efficacy of immune cell-mediated immunotherapy. Meanwhile, FLASH RT could activate the tumor immune microenvironment and transform "cold'' tumors into ''hot'' ones, consequently boosting local and systemic anti-tumor immunity and expanding the therapeutic benefits of ICIs. Moreover, FLASH might attenuate immunoinflammatory responses and minimize the incidence of radiation-related adverse events, allowing for the potentially safer and promising clinical application of combing FLASH RT with ICI therapy. Nevertheless, data on this treatment modality is currently lacking, and several barriers remain to be addressed, including the logistical bottlenecks, technical hurdles, limited availability, and unclear biological mechanisms. Further research is warranted in the future.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoy…
Zitieren
APA
Wang, Y., Qi, S. N., Bi, N., & Li, Y. X. (2025). FLASH radiotherapy combined with immunotherapy: From biological mechanisms to blockbuster therapeutics. Translational Oncology, 51, 102183. https://doi.org/10.1016/j.tranon.2024.102183
Vancouver
Wang Y, Qi SN, Bi N, Li YX. FLASH radiotherapy combined with immunotherapy: From biological mechanisms to blockbuster therapeutics. Translational Oncology. 2025;51:102183. doi:10.1016/j.tranon.2024.102183
BibTeX
@article{Wang2025,
author = {Wang, Yu and Qi, Shu-Nan and Bi, Nan and Li, Ye-Xiong},
title = {FLASH radiotherapy combined with immunotherapy: From biological mechanisms to blockbuster therapeutics},
journal = {Translational Oncology},
year = {2025},
volume = {51},
pages = {102183},
doi = {10.1016/j.tranon.2024.102183}
}
EUVIMED